BRCAness allows for the expansion of the somatic lethality approach to tumors carrying deficiencies in tumor suppressor genes involved in homologous recombination (HR) defective cancers, possessing BRCA1, BRCA2, ATM, ATR, FANC, RAD51, BRIP1, or PALB2 mutations. The gene discussed is RAD51; the disease is cancer.